MTL-005

Details

Stereochemistry	ACHIRAL
Molecular Formula	C38H20B20N6O6.Cu
Molecular Weight	936.368
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Cu++].[O-][N+](=O)C1=C2[N-]C(C=C2)=C(C3=NC(C=C3)=C(C4=CC=C([N-]4)C(=C5C=CC1=N5)C6=CC(OC[C]789%10[B]%11%12%13[B]%14%15%16[B]%17%18%19[B]%11%14%20[B]%17%21%22[B]%18%23%24[B]%15%19%25[B]7%12%16[B]8%23%25[C]9%21%24[B]%10%13%20%22)=CC=C6)[N+]([O-])=O)C%26=CC=CC(OC[C]%27%28%29%30[B]%31%32%33[B]%34%35%36[B]%37%38%39[B]%31%34%40[B]%37%41%42[B]%38%43%44[B]%35%39%45[B]%27%32%36[B]%28%43%45[C]%29%41%44[B]%30%33%40%42)=C%26

InChI

InChIKey=GJNAQHWCHVFMKD-XSUIMNIJSA-N

InChI=1S/C38H20B20N6O6.Cu/c65-63(66)33-27-11-7-23(59-27)31(19-3-1-5-21(15-19)69-17-37-35-39(37)43(35)44(35)40(35,37)48(37)47(37,39)51(39,43)55(43,44)52(40,44,48)57(47,48,51)55)24-8-12-28(60-24)34(64(67)68)30-14-10-26(62-30)32(25-9-13-29(33)61-25)20-4-2-6-22(16-20)70-18-38-36-41(38)45(36)46(36)42(36,38)50(38)49(38,41)53(41,45)56(45,46)54(42,46,50)58(49,50,53)56;/h1-16H,17-18H2;/q-2;+2/b31-23-,31-24-,32-25-,32-26-,33-27+,33-29+,34-28+,34-30+;

HIDE SMILES / InChI

Molecular Formula	C38H20B20N6O6
Molecular Weight	872.822
Charge	-2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Cu
Molecular Weight	63.546
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Substance Class	Chemical Created by `admin` on `Wed Apr 02 10:43:06 GMT 2025` Edited by `admin` on `Wed Apr 02 10:43:06 GMT 2025`
Record UNII	6LEC6S4MTY
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MTL-005

Code

English

MTL005

Preferred Name

English

COPPER MESO-5,15-BIS(3-((1,2-DICARBA-CLOSODODECABORANYL)METHOXY)PHENYL)-MESO-10,20-DINITROPORPHYRIN

Systematic Name

English

COPPER, (5,15-BIS(3-(1,2-DICARBADODECABORAN(12)-1-YLMETHOXY)PHENYL)-10,20-DINITRO-21H,23H-PORPHINATO(2-)-.KAPPA.N21,.KAPPA.N22,.KAPPA.N23,.KAPPA.N24)-, (SP-4-1)-

Systematic Name

English

(SP-4-1)-(5,15-BIS(3-(1,2-DICARBADODECABORAN(12)-1-YLMETHOXY)PHENYL)-10,20-DINITRO-21H,23H-PORPHINATO(2-)-.KAPPA.N21,.KAPPA.N22,.KAPPA.N23,.KAPPA.N24)COPPER

Common Name

English

Code System Code Type Description

FDA UNII

6LEC6S4MTY

Created by admin on Wed Apr 02 10:43:06 GMT 2025 , Edited by admin on Wed Apr 02 10:43:06 GMT 2025

PRIMARY

CAS

1030303-53-7

Created by admin on Wed Apr 02 10:43:06 GMT 2025 , Edited by admin on Wed Apr 02 10:43:06 GMT 2025

PRIMARY

SMS_ID

100000183875

Created by admin on Wed Apr 02 10:43:06 GMT 2025 , Edited by admin on Wed Apr 02 10:43:06 GMT 2025

PRIMARY

Related Record Type Details


					6LEC6S4MTY

MTL-005

ACTIVE MOIETY

Comments:

Drugs: MTL 005(Primary), Cisplatin; Indication: For Head and neck cancer; Focus: Adverse reactions, First in man; Sponsor: MorEx Development Partners; Most Recent Events: 27 Mar 2015 New trial record, 11 Mar 2015 Part 1 of this trial has been completed and preliminary data have been reported at the 30th Conference on Clinical and Experimental Research in Radiation Oncology (CERRO), according to a MorEx media release.

Amount:


					6LEC6S4MTY

MTL-005

ACTIVE MOIETY

Comments:

Originator: Morvus Technology; Developer: MorEx Development Partners; Class: Metalloporphyrin, Radiation-sensitising agent, Radiosensitiser; Mechanism of Action: Reactive oxygen species stimulant; Orphan Drug Status: Yes for Head and neck cancer; On Fast track: No; New Molecular Entity: Yes; Available For Licensing: Yes; Highest Development Phases: Phase I for Head and neck cancer, Preclinical for Breast cancer; Most Recent Events: 26 Mar 2015 MTL 005 is available for licensing as of 26 Mar 2015. http://www.morexdevelopments.com/partnering.html

Amount:


					6LEC6S4MTY

MTL-005

ACTIVE MOIETY

Comments:

MTL-005 is a boronated metalloporphyrin in development as a radio-enhancer: a drug given to patients prior to conventional radiotherapy and designed to amplify the effect of radiotherapy within the tumour, without affecting surrounding cells. It does not appear to be pharmacologically active and, as such, it is expected to have a good safety profile. Structure of MTL-005: (copper meso-5, 15-Bis(3-(( 1,2-Dicarba-closododecaboranyl)methoxy)phenyl)-meso-10,20-dinitroporphyrin) MTL-005 preferentially accumulates in tumour cells and interacts with the X-rays to generate reactive oxygen species that selectively kill the tumour cells. Evidence suggests that MTL-005 can enhance the effects of radiation regardless of the oxygen status of the target tumour.

Amount: